Schäfer Markus, Müllhaupt Beat, Clavien Pierre-Alain
Department of Surgery and Division of Gastroenterology, University of Zürich, Zürich, Switzerland.
Ann Surg. 2002 Aug;236(2):137-48. doi: 10.1097/00000658-200208000-00001.
To review the current status of pancreatoduodenectomy for pancreatic cancer and chronic pancreatitis using evidence-based methodology.
Despite improved results of pancreatoduodenectomy over the recent years, the reputation of the Whipple procedure and its main modifications has remained poor. In addition, the current status of newer modifications of standard pancreatoduodenectomy is still under debate.
Medline search and manual cross-referencing were performed to identify all relevant articles for classification and analysis according to their quality of evidence. The search was limited to articles published between 1990 and 2001.
The mortality rate of pancreatoduodenectomy has declined to less than 5% for chronic pancreatitis and 3% to 8% for pancreatic cancer. In contrast, overall morbidity rates remain high, ranging between 20% and 70%. Delayed gastric emptying represents almost half of all complications. The overall 5-year survival rate for patients with pancreatic cancer remains poor, ranging between 5% and 15%, with a median survival of 13 to 17 months. Mortality and morbidity are not related to the type of pancreatoduodenectomy; however, patients with pancreatic cancer tend to be at increased risk for complications. Extended lymph node dissection and portal vein resection can be performed with similar mortality and morbidity rates as standard procedures, but without apparent survival benefits in the long term. Major relief of pain is achieved in 70% to 100% of patients with chronic pancreatitis.
Pancreatoduodenectomy and its main modifications are safe and effective treatment modalities, especially in experienced centers with a high patient volume. For chronic pancreatitis, surgical resection provides major relief of pain and thus increased quality of life. Overall survival for patients with pancreatic cancer is determined predominantly by the pathology within the resected specimen.
采用循证医学方法回顾胰腺癌和慢性胰腺炎胰十二指肠切除术的现状。
尽管近年来胰十二指肠切除术的效果有所改善,但惠普尔手术及其主要改良术式的声誉仍然不佳。此外,标准胰十二指肠切除术的新型改良术式的现状仍存在争议。
进行Medline检索并人工交叉引用,以识别所有相关文章,并根据证据质量进行分类和分析。检索限于1990年至2001年发表的文章。
慢性胰腺炎胰十二指肠切除术的死亡率已降至5%以下,胰腺癌的死亡率为3%至8%。相比之下,总体发病率仍然很高,在20%至70%之间。胃排空延迟几乎占所有并发症的一半。胰腺癌患者的总体5年生存率仍然很低,在5%至15%之间,中位生存期为13至17个月。死亡率和发病率与胰十二指肠切除术的类型无关;然而,胰腺癌患者发生并发症的风险往往增加。扩大淋巴结清扫和门静脉切除的死亡率和发病率与标准手术相似,但长期来看没有明显的生存益处。70%至100%的慢性胰腺炎患者疼痛得到显著缓解。
胰十二指肠切除术及其主要改良术式是安全有效的治疗方式,尤其是在患者量大且经验丰富的中心。对于慢性胰腺炎,手术切除可显著缓解疼痛,从而提高生活质量。胰腺癌患者的总体生存主要取决于切除标本的病理情况。